Cardiovascular Manifestations of COVID-19

Study Overview
=================
Brief Summary
-----------------
Electronic medical record review of de-identified patients who tested positive for COVID-19 (using a PCR test) at Methodist Dallas Medical Center (MDMC) from June 2020 until the date of IRB approval. Data will be collected on de-identified patients that test positive for COVID-19 (using a PCR test) at MDMC from the date of IRB approval until December 2022. Disclaimer: Any cost associated with the procedures stated herein will be billed directly to you or to your insurance (as applicable)

Detailed Description
-----------------
Electronic medical record review of de-identified patients who tested positive for COVID-19 (using a PCR test) at Methodist Dallas Medical Center (MDMC) from June 2020 until the date of IRB approval. Data will be collected on de-identified patients that test positive for COVID-19 (using a PCR test) at MDMC from the date of IRB approval until December 2022. Variables include patient baseline characteristics, patient presentation, imaging and labs. Disclaimer: Any cost associated with the procedures stated herein will be billed directly to you or to your insurance (as applicable)

Official Title
-----------------
Cardiovascular Manifestations of COVID-19

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Other: Chart review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized patient Adult over 18 years Positive COVID-19 PCR Test Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Retrospective Cohort<br>Review electronic medical records of de-identified patients that tested positive for COVID-19 (using a PCR test) at Methodist Dallas Medical Center (MDMC) from June 2020 until December 2022 | Other: Chart review<br>* Chart review<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart failure | Presence or absence | March 2020 - June 2021 | 
| Tamponade | Presence or absence | March 2020 - June 2021 | 
| Pericardial Effusion | Presence or absence | March 2020 - June 2021 | 
| Myocarditis | Presence or absence | March 2020 - June 2021 | 
| Pericarditis | Presence or absence | March 2020 - June 2021 | 
| Arrythmias | Presence or absence | March 2020 - June 2021 | 
| Troponin I | Level | March 2020 - June 2021 | 
| N-terminal prohormone BNP | Level | March 2020 - June 2021 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stroke | Presence or absence | March 2020 - June 2021 | 
| Myocardial infarction | Type | March 2020 - June 2021 | 
| Shock | Presence or absence | March 2020 - June 2021 | 
| Deep venous thrombosis | Presence or absence | March 2020 - June 2021 | 
| Discharge disposition | Location | March 2020 - June 2021 | 
| Primary diagnosis | Diagnosis upon discharge | March 2020 - June 2021 | 
| Rate of ICU admission/transfer | Rates | March 2020 - June 2021 | 
| Total hospital length of stay | Number of Days | March 2020 - June 2021 | 
| ICU length of stay | Number of Days | March 2020 - June 2021 | 
| Percentage of patients in cohort that had EKG testing or Echocardiography | Percentage | March 2020 - June 2021 |